As Director of CMC, Dr. Brower is responsible for developing and executing the CMC strategy, managing external CDMO partners, and supporting regulatory activities required for product commercialization and delivery.

Dr. Brower earned his Ph.D. in biology from Johns Hopkins University, where his research concentrated on the thermodynamics and biophysical analysis of naturally occurring HIV variability and its effects on anti-HIV drug potency. Following his doctorate, he pursued postdoctoral studies at Johns Hopkins Medical School, where he investigated the structural and biochemical mechanisms underlying how cancer-associated mutations in kinases, and other proteins, negatively impacted cellular processes and supported cancer progression. His industry experience includes roles at Catalent and NextCure, where he gained expertise in forging fruitful cross-functional collaborations and focused on development, tech transfer, and manufacturing of a diverse array of modalities including monoclonal antibodies, antibody-drug conjugates, fusion proteins, gene therapy vectors, and numerous vaccine technologies (virus-like particles (VLPs), virus-like replicon particles (VRPs), multivalent protein-polysaccharide conjugates, and nanoparticles).

Dr. Brower is dedicated to harnessing his passion for technology, science, and innovation to provide patients with safe, effective, and cutting-edge therapies.